Home LiteratureArticle Details
PMID: 11264346 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.

Journal of virology ·Vol. 75 ·No. 8 ·2001-04-00 ·Pages 3568-80

Martín J, LaBranche CC, González-Scarano F

Abstract

Human immunodeficiency virus type 1 (HIV-1) infects and induces syncytium formation in microglial cells from the central nervous system (CNS). A primary isolate (HIV-1(BORI)) was sequentially passaged in cultured microglia, and the isolate recovered (HIV-1(BORI-15)) showed high levels of fusion and replicated more efficiently in microglia (J. M. Strizki, A. V. Albright, H. Sheng, M. O'Connor, L. Perrin, and F. González-Scarano, J. Virol. 70:7654-7662, 1996). The parent and adapted viruses used CCR5 as coreceptor. Recombinant viruses demonstrated that the syncytium-inducing phenotype was associated with four amino acid differences in the V1/V2 region of the viral gp120 (J. T. C. Shieh, J. Martin, G. Baltuch, M. H. Malim, and F. González-Scarano, J. Virol. 74:693-701, 2000). We produced luciferase-reporter, env-pseudotyped viruses using plasmids containing env sequences from HIV-1(BORI), HIV-1(BORI-15), and the V1/V2 region of HIV-1(BORI-15) in the context of HIV-1(BORI) env (named rBORI, rB15, and rV1V2, respectively). The pseudotypes were used to infect cells expressing various amounts of CD4 and CCR5 on the surface. In contrast to the parent recombinant, the rB15 and rV1V2 pseudotypes retained their infectability in cells expressing low levels of CD4 independent of the levels of CCR5, and they infected cells expressing CD4 with a chimeric coreceptor containing the third extracellular loop of CCR2b in the context of CCR5 or a CCR5 Delta4 amino-terminal deletion mutant. The VH-rB15 and VH-rV1V2 recombinant viruses were more sensitive to neutralization by a panel of HIV-positive sera than was VH-rBORI. Interestingly, the CD4-induced 17b epitope on gp120 was more accessible in the rB15 and rV1V2 pseudotypes than in rBORI, even before CD4 binding, and concomitantly, the rB15 and rV1V2 pseudotypes were more sensitive to neutralization with the human 17b monoclonal antibody. Adaptation to growth in microglia--cells that have reduced expression of CD4 in comparison with other cell types--appears to be associated with changes in gp120 that modify its ability to utilize CD4 and CCR5. Changes in the availability of the 17b epitope indicate that these affect conformation. These results imply that the process of adaptation to certain tissue types such as the CNS directly affects the interaction of HIV-1 envelope glycoproteins with cell surface components and with humoral immune responses.

MeSH Terms
Adaptation, Biological Antibodies, Monoclonal/immunology Brain CD4 Antigens/genetics,metabolism Cell Line Cells, Cultured Enzyme-Linked Immunosorbent Assay Epitopes/immunology Genes, Reporter HIV Antibodies/immunology HIV Envelope Protein gp120/chemistry,immunology,metabolism HIV-1/chemistry,immunology,metabolism,physiology Humans Immune Sera/immunology Luciferases/genetics,metabolism Microglia/metabolism,virology Neutralization Tests Receptors, CCR2 Receptors, CCR5/genetics,metabolism Receptors, Chemokine/genetics,metabolism Recombinant Fusion Proteins/genetics,metabolism Sequence Deletion/genetics Serial Passage Transfection
Chemicals
Antibodies, Monoclonal CCR2 protein, human CD4 Antigens Epitopes HIV Antibodies HIV Envelope Protein gp120 Immune Sera Receptors, CCR2 Receptors, CCR5 Receptors, Chemokine Recombinant Fusion Proteins Luciferases
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Martín J
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
LaBranche C C
González-Scarano F
References (117)
117 references, click to expand
  1. Identification of a major co-receptor for primary isolates of HIV-1.
    Nature. 1996 Jun 20;381(6584):661-6 PMID: 8649511
  2. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
    Nature. 1996 Jun 20;381(6584):667-73 PMID: 8649512
  3. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
    Cell. 1996 Jun 28;85(7):1135-48 PMID: 8674119
  4. The relationship between AIDS dementia complex and the presence of macrophage tropic and non-syncytium inducing isolates of human immunodeficiency virus type 1 in the cerebrospinal fluid.
    J Neurovirol. 1996 Jun;2(3):152-7 PMID: 8799207
  5. Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism.
    J Virol. 1996 Nov;70(11):7654-62 PMID: 8892885
  6. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity.
    Cell. 1996 Nov 1;87(3):437-46 PMID: 8898197
  7. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):179-83 PMID: 8906795
  8. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):184-7 PMID: 8906796
  9. Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.
    Science. 1996 Dec 13;274(5294):1924-6 PMID: 8943208
  10. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.
    Nature. 1997 Feb 13;385(6617):645-9 PMID: 9024664
  11. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues.
    J Virol. 1997 Mar;71(3):2059-71 PMID: 9032338
  12. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection.
    J Virol. 1997 May;71(5):3932-9 PMID: 9094670
  13. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro.
    J Exp Med. 1997 May 5;185(9):1681-91 PMID: 9151905
  14. HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor.
    EMBO J. 1997 May 15;16(10):2599-609 PMID: 9184207
  15. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion.
    J Virol. 1997 Jul;71(7):5003-11 PMID: 9188565
  16. CC chemokine receptor 5-mediated signaling and HIV-1 Co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion.
    J Biol Chem. 1997 Aug 8;272(32):19771-6 PMID: 9242636
  17. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.
    J Virol. 1997 Sep;71(9):6305-14 PMID: 9261347
  18. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.
    J Virol. 1997 Oct;71(10):7478-87 PMID: 9311827
  19. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.
    J Exp Med. 1997 Oct 20;186(8):1373-81 PMID: 9334377
  20. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
    AIDS Res Hum Retroviruses. 1997 Oct 10;13(15):1291-9 PMID: 9339846
  21. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
    J Virol. 1997 Dec;71(12):9808-12 PMID: 9371651
  22. Direct ex vivo flow cytometric analysis of human microglial cell CD4 expression: examination of central nervous system biopsy specimens from HIV-seropositive patients and patients with other neurological disease.
    AIDS. 1997 Nov 15;11(14):1699-708 PMID: 9386804
  23. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.
    J Virol. 1998 Jan;72(1):279-85 PMID: 9420225
  24. Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype.
    J Virol. 1998 Jan;72(1):512-9 PMID: 9420253
  25. A new classification for HIV-1.
    Nature. 1998 Jan 15;391(6664):240 PMID: 9440686
  26. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5.
    J Virol. 1998 Feb;72(2):1160-4 PMID: 9445013
  27. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.
    J Virol. 1998 Mar;72(3):1886-93 PMID: 9499040
  28. Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates.
    J Virol. 1998 Mar;72(3):1918-24 PMID: 9499044
  29. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.
    J Virol. 1998 Apr;72(4):2855-64 PMID: 9525605
  30. Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia.
    J Virol. 1998 Apr;72(4):3351-61 PMID: 9525662
  31. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1.
    J Virol. 1998 Apr;72(4):3464-8 PMID: 9525683
  32. Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia.
    J Virol. 1998 May;72(5):4243-9 PMID: 9557714
  33. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
    J Virol. 1998 Jun;72(6):4694-703 PMID: 9573233
  34. A role for carbohydrates in immune evasion in AIDS.
    Nat Med. 1998 Jun;4(6):679-84 PMID: 9623976
  35. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    Science. 1998 Jun 19;280(5371):1884-8 PMID: 9632381
  36. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
    Science. 1998 Jun 19;280(5371):1949-53 PMID: 9632396
  37. Chemokine receptors in the human brain and their relationship to HIV infection.
    J Neurovirol. 1998 Jun;4(3):301-11 PMID: 9639073
  38. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  39. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  40. Chemokine receptors in HIV-1 infection of the central nervous system.
    Semin Immunol. 1998 Jun;10(3):203-13 PMID: 9653047
  41. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
    J Virol. 1998 Aug;72(8):6332-8 PMID: 9658072
  42. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
    Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73 PMID: 9671771
  43. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies.
    Virology. 1998 Sep 1;248(2):394-405 PMID: 9721247
  44. Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients.
    J Virol. 1998 Nov;72(11):9045-53 PMID: 9765449
  45. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates.
    J Virol. 1999 Jan;73(1):205-13 PMID: 9847323
  46. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.
    J Biol Chem. 1999 Jan 22;274(4):1905-13 PMID: 9890944
  47. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.
    J Biol Chem. 1999 Apr 2;274(14):9617-26 PMID: 10092648
  48. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.
    J Virol. 1999 Dec;73(12):10310-9 PMID: 10559349
  49. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein.
    J Biol Chem. 1999 Dec 3;274(49):34719-27 PMID: 10574939
  50. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.
    J Virol. 2000 Jan;74(1):326-33 PMID: 10590121
  51. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
    Cell. 1996 Jun 28;85(7):1149-58 PMID: 8674120
  52. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
    Science. 1996 Jun 28;272(5270):1955-8 PMID: 8658171
  53. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry.
    AIDS. 1996 Jun;10(6):573-85 PMID: 8780811
  54. Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains.
    J Virol. 1999 May;73(5):4062-73 PMID: 10196302
  55. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
    Nat Med. 1999 May;5(5):512-7 PMID: 10229227
  56. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
    N Engl J Med. 1999 May 27;340(21):1605-13 PMID: 10341272
  57. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
    J Virol. 1999 Jul;73(7):5294-300 PMID: 10364275
  58. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Biochemistry. 1999 Jul 20;38(29):9405-16 PMID: 10413516
  59. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication.
    J Virol. 1999 Oct;73(10):8120-6 PMID: 10482561
  60. Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains.
    J Virol. 2000 Jan;74(2):693-701 PMID: 10623731
  61. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
    Proc Natl Acad Sci U S A. 2000 May 9;97(10):5639-44 PMID: 10779565
  62. Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):871-82 PMID: 10875613
  63. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    J Virol. 2000 Aug;74(15):6769-76 PMID: 10888615
  64. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.
    J Virol. 2000 Sep;74(17):7824-33 PMID: 10933689
  65. Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages.
    J Virol. 2000 Nov;74(22):10852-9 PMID: 11044136
  66. The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses.
    J Virol. 2000 Dec;74(23):10984-93 PMID: 11069993
  67. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 PMID: 6096719
  68. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8 PMID: 6083454
  69. Acute encephalopathy coincident with seroconversion for anti-HTLV-III.
    Lancet. 1985 Nov 30;2(8466):1206-8 PMID: 2866290
  70. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.
    Science. 1986 Sep 5;233(4768):1089-93 PMID: 3016903
  71. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.
    Proc Natl Acad Sci U S A. 1986 Sep;83(18):7089-93 PMID: 3018755
  72. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.
    Cell. 1986 Nov 7;47(3):333-48 PMID: 3094962
  73. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex.
    Science. 1988 Feb 5;239(4840):586-92 PMID: 3277272
  74. Distinct biological and serological properties of human immunodeficiency viruses from the brain.
    Ann Neurol. 1988;23 Suppl:S58-61 PMID: 3258140
  75. Neuropathological changes in early HIV-1 dementia.
    Ann Neurol. 1989 Nov;26(5):681-4 PMID: 2817844
  76. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
    J Biol Chem. 1990 Jun 25;265(18):10373-82 PMID: 2355006
  77. Specific tropism of HIV-1 for microglial cells in primary human brain cultures.
    Science. 1990 Aug 3;249(4968):549-53 PMID: 2200125
  78. HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies.
    Virology. 1991 Feb;180(2):583-90 PMID: 1989385
  79. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.
    N Engl J Med. 1991 Apr 4;324(14):954-60 PMID: 1900576
  80. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.
    Science. 1991 Jul 5;253(5015):71-4 PMID: 1905842
  81. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes.
    J Virol. 1991 Aug;65(8):3973-85 PMID: 1830110
  82. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.
    J Exp Med. 1991 Aug 1;174(2):407-15 PMID: 1713252
  83. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    J Virol. 1992 Jan;66(1):235-43 PMID: 1727487
  84. Pathology of HIV-1 infection of the central nervous system. A review.
    J Neuropathol Exp Neurol. 1992 Jan;51(1):3-11 PMID: 1740672
  85. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
    Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1335-9 PMID: 1741386
  86. Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2213-7 PMID: 1549584
  87. Packaging system for rapid production of murine leukemia virus vectors with variable tropism.
    J Virol. 1992 Aug;66(8):5110-3 PMID: 1321291
  88. Early viral brain invasion in iatrogenic human immunodeficiency virus infection.
    Neurology. 1992 Sep;42(9):1736-9 PMID: 1513462
  89. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding.
    J Virol. 1993 Jan;67(1):584-8 PMID: 8416385
  90. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
    J Virol. 1993 Mar;67(3):1461-71 PMID: 8437224
  91. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism.
    J Virol. 1993 Jun;67(6):3649-52 PMID: 8497073
  92. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.
    J Virol. 1993 Jun;67(6):3674-9 PMID: 8497077
  93. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    J Virol. 1993 Jul;67(7):3978-88 PMID: 7685405
  94. Productive infection of human fetal microglia by HIV-1.
    Am J Pathol. 1993 Oct;143(4):1032-9 PMID: 8213999
  95. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.
    J Virol. 1993 Dec;67(12):7383-93 PMID: 7693970
  96. Clinical-neuropathologic correlation in HIV-associated dementia.
    Neurology. 1993 Nov;43(11):2230-7 PMID: 8232935
  97. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
    J Virol. 1994 Jan;68(1):469-84 PMID: 7504741
  98. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    J Virol. 1995 Jan;69(1):101-9 PMID: 7527081
  99. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.
    J Virol. 1995 Jan;69(1):39-48 PMID: 7983734
  100. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome.
    N Engl J Med. 1995 Apr 6;332(14):934-40 PMID: 7877652
  101. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    Proc Natl Acad Sci U S A. 1999 May 11;96(10):5698-703 PMID: 10318947
  102. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.
    Proc Natl Acad Sci U S A. 1999 May 25;96(11):6359-64 PMID: 10339592
  103. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
    Annu Rev Immunol. 1999;17:657-700 PMID: 10358771
  104. Neuropathology of human immunodeficiency virus infection.
    Brain Pathol. 1991 Apr;1(3):163-75 PMID: 1669705
  105. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.
    AIDS Res Hum Retroviruses. 1993 Nov;9(11):1051-3 PMID: 8312047
  106. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.
    J Virol. 1994 Apr;68(4):2253-9 PMID: 8139010
  107. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences.
    J Virol. 1994 Jul;68(7):4643-49 PMID: 8207838
  108. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences.
    J Virol. 1994 Nov;68(11):7467-81 PMID: 7933130
  109. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome.
    Ann Neurol. 1994 Oct;36(4):673-6 PMID: 7944304
  110. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
    J Virol. 1995 Apr;69(4):2271-8 PMID: 7533854
  111. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  112. Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence.
    Curr Top Microbiol Immunol. 1995;202:89-104 PMID: 7587373
  113. Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread.
    Virology. 1995 Oct 20;213(1):70-9 PMID: 7483281
  114. Long-term productive human immunodeficiency virus-1 infection in human infant microglia.
    Am J Pathol. 1995 Nov;147(5):1200-6 PMID: 7485383
  115. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells.
    J Virol. 1996 Feb;70(2):1310-6 PMID: 8551601
  116. HIV-1 infection of cultured human adult oligodendrocytes.
    Virology. 1996 Mar 1;217(1):211-9 PMID: 8599205
  117. Functional characterization of the V1V2 region of human immunodeficiency virus type 1.
    Virology. 1996 Jun 15;220(2):436-49 PMID: 8661394
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2001-04-00
Pages
3568-80
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC114848
Subset
IM
Grants
NINDS NIH HHS · R01 NS035734 · United States
NINDS NIH HHS · NS-35734 · United States
NIMH NIH HHS · MH-58958 · United States
NINDS NIH HHS · P01 NS027405 · United States
NINDS NIH HHS · NS-27405 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com